By Professor Elgene Lim

Journal articles

Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A; Boyle F; Jerusalem G; Stahel R; Aebi S; Green M; Karlsson P; Kössler I; Láng I; Hiltbrunner A; Bernhard J; Fournarakou S; Kammler R; Maibach R; Rabaglio M; Ribi K; Roschitzki H; Roux S; Ruepp B; Mahoney C; Price K; Blacher L; Scolese T; Scott K; Lippert S; Zielinski T; Mastropasqua M; Andrighetto S; Dell'Orto P; Renne G; Pruneri G; Dellapasqua S; Iorfida M; Cancello G; Montagna E; Cardillo A; Peruzzotti G; Ghisini R; Luini A; Veronesi U; Gentilini O; Zurrida S; Curigliano G; Nole F; Orecchia R; Leonardi MC; Baratella P; Chifu C; Sargenti M; Crivellari D; Morassut S; Mileto M; Piccoli E; Veronesi A; Magri MD; Buonadonna A; Candiani E; Carbone A; Perin T; Volpe R; Roncadin M; Arcicasa M; Coran F; Lagrassa M; Recalcati A; Limonta ME; Tricomi P; Fenaroli P; Candiago E; Cattaneo L; Gianatti A; Santini D; Maweja S; Delvenne P; Rorive A; Collignon J; Garbay JR; Mathieu MC; Galatius H; Hoffmann J; Schousen P, 2018, 'Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial', The Lancet Oncology, 19, pp. 1385 - 1393, http://dx.doi.org/10.1016/S1470-2045(18)30380-2

Lim E; Beith J; Boyle F; de Boer R; Hui R; McCarthy N; Redfern A; Wade T; Woodward N, 2018, 'Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 14, pp. 12 - 21, http://dx.doi.org/10.1111/ajco.13065

Boyle F; Beith J; Burslem K; de Boer R; Hui R; Lim E; McCarthy N; Redfern A; Woodward N, 2018, 'Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm', Asia-Pacific Journal of Clinical Oncology, 14, pp. 3 - 11, http://dx.doi.org/10.1111/ajco.13064

Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede H, 2018, 'Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia', Clinical Endocrinology, 89, pp. 280 - 296, http://dx.doi.org/10.1111/cen.13735

Robinson DH; Churilov L; Lin NU; Lim E; Seah D, 2018, 'Attitudes of patients with metastatic cancer towards research biopsies', Asia-Pacific Journal of Clinical Oncology, 14, pp. 231 - 238, http://dx.doi.org/10.1111/ajco.12783

Roswall P; Bocci M; Bartoschek M; Li H; Kristiansen G; Jansson S; Lehn S; Sjölund J; Reid S; Larsson C; Eriksson P; Anderberg C; Cortez E; Saal LH; Orsmark-Pietras C; Cordero E; Haller BK; Häkkinen J; Burvenich IJG; Lim E; Orimo A; Höglund M; Rydén L; Moch H; Scott AM; Eriksson U; Pietras K, 2018, 'Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling', Nature Medicine, 24, pp. 463 - 473, http://dx.doi.org/10.1038/nm.4494

Wang Y; Li YM; Baitsch L; Huang A; Xiang Y; Tong H; Lako A; Von T; Choi C; Lim E; Min J; Li L; Stegmeier F; Schlegel R; Eck MJ; Gray NS; Mitchison TJ; Zhao JJ, 2018, 'Erratum: Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells (eLife (2014) 3 (e01763) PII: e36414)', eLife, 7, http://dx.doi.org/10.7554/eLife.36414

Hastie R; Lim E; Sluka P; Campbell L; Horne AW; Ellett L; Hannan NJ; Brownfoot F; Kaitu'u-Lino TJ; Tong S, 2018, 'Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy', EBioMedicine, 29, pp. 166 - 176, http://dx.doi.org/10.1016/j.ebiom.2018.01.041

Lim E; Portman N; Wahlroos S; Parker A; Segara D, 2017, 'Endocrine therapy for breast cancer: A Renaissance', The Endocrinologist, pp. 13 - 14

Meeusen E; Lim E; Mathivanan S, 2017, 'Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy', Proteomics, 17, http://dx.doi.org/10.1002/pmic.201600442

Lim E; Johnson SF; Geyer M; Serra V; Shapiro GI, 2017, 'Sensitizing HR-proficient cancers to PARP inhibitors', Molecular and Cellular Oncology, 4, http://dx.doi.org/10.1080/23723556.2017.1299272

Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS, 2017, 'Neoadjuvant interferons: Critical for effective PD-1–based immunotherapy in TNBC', Cancer Immunology Research, 5, pp. 871 - 884, http://dx.doi.org/10.1158/2326-6066.CIR-17-0150

Law AMK; Lim E; Ormandy CJ; Gallego-Ortega D, 2017, 'Erratum: The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy (Endocrine-related cancer (2017) 24 4 (R123-R144) PII: ERC160404e)', Endocrine-related cancer, 24, pp. X1, http://dx.doi.org/10.1530/ERC-16-0404e

Law AMK; Lim E; Ormandy CJ; Gallego-Ortega D, 2017, 'The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy', Endocrine-Related Cancer, 24, pp. R123 - R144, http://dx.doi.org/10.1530/ERC-16-0404

Dreijerink KMA; Groner AC; Vos ESM; Font-Tello A; Gu L; Chi D; Reyes J; Cook J; Lim E; Lin CY; de Laat W; Rao PK; Long HW; Brown M, 2017, 'Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer', Cell Reports, 18, pp. 2359 - 2372, http://dx.doi.org/10.1016/j.celrep.2017.02.025

Haupt S; Vijayakumaran R; Miranda PJ; Burgess A; Lim E; Haupt Y, 2017, 'The role of MDM2 and MDM4 in breast cancer development and prevention', Journal of molecular cell biology, 9, pp. 53 - 61, http://dx.doi.org/10.1093/jmcb/mjx007

Metzger O; Mandrekar S; Ciruelos E; Loibl S; Valagussa P; Demichele AM; Lim E; Tripathy D; Winer E; Huang C; Khoeler M; Carey L; Francis P; Miller K; Goel S; Goetz MP; Prat A; Loi S; Krop I; Gianni L, 2017, 'PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer', Annals of Oncology, 28, pp. v107 - v108, http://dx.doi.org/10.1093/annonc/mdx365.087

Chaffer CL; San Juan BP; Lim E; Weinberg RA, 2016, 'EMT, cell plasticity and metastasis', Cancer and Metastasis Reviews, 35, pp. 645 - 654, http://dx.doi.org/10.1007/s10555-016-9648-7

Lim E; Tarulli G; Portman N; Hickey TE; Tilley WD; Palmieri C, 2016, 'Pushing estrogen receptor around in breast cancer', Endocrine-Related Cancer, 23, pp. T227 - T241, http://dx.doi.org/10.1530/ERC-16-0427

Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI, 2016, 'CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer', Cell Reports, 17, pp. 2367 - 2381, http://dx.doi.org/10.1016/j.celrep.2016.10.077

Ramchand SK; Lim E; Grossmann M, 2016, 'Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: how should the skeletal and vascular side effects be assessed and managed?', Clinical Endocrinology, 85, pp. 689 - 693, http://dx.doi.org/10.1111/cen.13172

Lim E; Palmieri C; Tilley WD, 2016, 'Renewed interest in the progesterone receptor in breast cancer', British Journal of Cancer, 115, pp. 909 - 911, http://dx.doi.org/10.1038/bjc.2016.303

Samanta S; Sun H; Goel HL; Pursell B; Chang C; Khan A; Greiner DL; Cao S; Lim E; Shultz LD; Mercurio AM, 2016, 'IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG', Oncogene, 35, pp. 1111 - 1121, http://dx.doi.org/10.1038/onc.2015.164

Burgess A; Chia KM; Haupt S; Thomas D; Haupt Y; Lim E, 2016, 'Clinical overview of MDM2/X-targeted therapies', Frontiers in Oncology, 6, http://dx.doi.org/10.3389/fonc.2016.00007

Neupane M; Clark AP; Landini S; Birkbak NJ; Eklund AC; Lim E; Culhane AC; Barry WT; Schumacher SE; Beroukhim R; Szallasi Z; Vidal M; Hill DE; Silver DP, 2016, 'MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy', Cancer Discovery, 6, pp. 45 - 58, http://dx.doi.org/10.1158/2159-8290.CD-15-0341

Wee ZN; Yatim SMJM; Kohlabauer VK; Feng M; Goh JY; Bao Y; Lee PL; Zhang S; Wang PP; Lim E; Tam WL; Cai Y; Ditzel HJ; Hoon DSB; Tan EY; Yu Q, 2015, 'Erratum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel (Nature Communications (2015) 6 (8746) DOI: 10.1038/ncomms9746)', Nature Communications, 6, http://dx.doi.org/10.1038/ncomms10054

Wee ZN; Yatim SMJM; Kohlbauer VK; Feng M; Goh JY; Yi B; Lee PL; Zhang S; Wang PP; Lim E; Tam WL; Cai Y; Ditzel HJ; Hoon DSB; Tan EY; Yu Q, 2015, 'IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel', Nature Communications, 6, http://dx.doi.org/10.1038/ncomms9746

Wang Y; Zhang T; Kwiatkowski N; Abraham BJ; Lee TI; Xie S; Yuzugullu H; Von T; Li H; Lin Z; Stover DG; Lim E; Wang ZC; Iglehart JD; Young RA; Gray NS; Zhao JJ, 2015, 'CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer', Cell, 163, pp. 174 - 186, http://dx.doi.org/10.1016/j.cell.2015.08.063

Chia KM; O’Brien M; Brown M; Lim E, 2015, 'Targeting the Androgen Receptor in Breast Cancer', Current Oncology Reports, 17, http://dx.doi.org/10.1007/s11912-014-0427-8

Chang C; Goel HL; Gao H; Pursell B; Shultz LD; Greiner DL; Ingerpuu S; Patarroyo M; Cao S; Lim E; Mao J; Kulju McKee K; Yurchenco PD; Mercurio AM, 2015, 'A laminin 511 matrix is regulated by Taz and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells', Genes and Development, 29, pp. 1 - 6, http://dx.doi.org/10.1101/gad.253682.114

Hu Y; Petit SA; Ficarro SB; Toomire KJ; Xie A; Lim E; Cao SA; Park E; Eck MJ; Scully R; Brown M; Marto JA; Livingston DM, 2014, 'PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination–mediated DNA repair', Cancer Discovery, 4, pp. 1430 - 1447, http://dx.doi.org/10.1158/2159-8290.CD-13-0891

Lu G; Zhang Q; Huang Y; Song J; Tomaino R; Ehrenberger T; Lim E; Liu W; Bronson RT; Bowden M; Brock J; Krop IE; Dillon DA; Gygi SP; Mills GB; Richardson AL; Signoretti S; Yaffe MB; Kaelin WG, 2014, 'Phosphorylation of ETS1 by src family kinases prevents its recognition by the COP1 tumor suppressor', Cancer Cell, 26, pp. 222 - 234, http://dx.doi.org/10.1016/j.ccr.2014.06.026

Lim E; Lin NU, 2014, 'Updates on the management of breast cancer brain metastases', Oncology (Williston Park), 28, pp. 572 - 578

Wang Y; Lee YM; Baitsch L; Huang A; Xiang Y; Tong H; Lako A; Von T; Choi C; Lim E; Min J; Li L; Stegmeier F; Schlegel R; Eck MJ; Gray NS; Mitchison TJ; Zhao JJ, 2014, 'MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells', eLife, 2014, http://dx.doi.org/10.7554/eLife.01763

Lim E; Ni M; Cao S; Hazra A; Tamimi RM; Brown M, 2014, 'Importance of breast cancer subtype in the development of androgen-receptor-directed therapy', Current Breast Cancer Reports, 6, pp. 71 - 78, http://dx.doi.org/10.1007/s12609-014-0140-5

Chen X; Iliopoulos D; Zhang Q; Tang Q; Greenblatt MB; Hatziapostolou M; Lim E; Tam WL; Ni M; Chen Y; Mai J; Shen H; Hu DZ; Adoro S; Hu B; Song M; Tan C; Landis MD; Ferrari M; Shin SJ; Brown M; Chang JC; Liu XS; Glimcher LH, 2014, 'XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway', Nature, 508, pp. 103 - 107, http://dx.doi.org/10.1038/nature13119

Tam WL; Lu H; Buikhuisen J; Soh BS; Lim E; Reinhardt F; Wu ZJ; Krall JA; Bierie B; Guo W; Chen X; Liu XS; Brown M; Lim B; Weinberg RA, 2013, 'Protein Kinase C α Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells', Cancer Cell, 24, pp. 347 - 364, http://dx.doi.org/10.1016/j.ccr.2013.08.005

McLaughlin SK; Olsen SN; Dake B; De Raedt T; Lim E; Bronson RT; Beroukhim R; Polyak K; Brown M; Kuperwasser C; Cichowski K, 2013, 'The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor', Cancer Cell, 24, pp. 365 - 378, http://dx.doi.org/10.1016/j.ccr.2013.08.004

Tichy JR; Lim E; Anders CK, 2013, 'Breast cancer in adolescents and young adults: A review with a focus on biology', JNCCN Journal of the National Comprehensive Cancer Network, 11, pp. 1060 - 1069, http://dx.doi.org/10.6004/jnccn.2013.0128

Buchwalter G; Hickey MM; Cromer A; Selfors LM; Gunawardane RN; Frishman J; Jeselsohn R; Lim E; Chi D; Fu X; Schiff R; Brown M; Brugge JS, 2013, 'PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells', Cancer Cell, 23, pp. 753 - 767, http://dx.doi.org/10.1016/j.ccr.2013.04.026

Ni M; Chen Y; Fei T; Li D; Lim E; Liu XS; Brown M, 2013, 'Amplitude modulation of androgen signaling by c-MYC', Genes and Development, 27, pp. 734 - 748, http://dx.doi.org/10.1101/gad.209569.112

Shen RR; Zhou AY; Kim E; Lim E; Habelhah H; Hahn WC, 2012, 'IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation', Molecular and Cellular Biology, 32, pp. 4756 - 4768, http://dx.doi.org/10.1128/MCB.00468-12

Lim E; Ni M; Hazra A; Tamimi R; Brown M, 2012, 'Elucidating the role of androgen receptors and breast cancer.', Clinical Investigation, 2, pp. 1003 - 1011

Lim E; Metzger-Filho O; Winer EP, 2012, 'Natural history of hormone receptor positive breast cancer', Oncology (Williston Park), 26, pp. 688 - 694

Lim E; Lin NU, 2012, 'New insights and emerging therapies in breast cancer brain metastases', Oncology (Williston Park), 26, pp. 652 - 659

Lim E; He HH; Chi D; Garber JE; Richardson A; Brown M, 2012, 'Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells.', Journal of Clinical Oncology, 30, pp. 576 - 576, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.576

Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE; Lindeman GJ, 2012, 'Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737', Proceedings of the National Academy of Sciences of the United States of America, 109, pp. 2766 - 2771, http://dx.doi.org/10.1073/pnas.1104778108

Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE; Lindeman GJ, 2012, 'Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics', Hereditary cancer in clinical practice, 10, pp. A25 - A25, http://dx.doi.org/10.1186/1897-4287-10-s2-a25

Ni M; Chen Y; Bailey ST; Imai Y; Liu XS; Brown M, 2011, 'Abstract 941: Targeting androgen receptor in estrogen receptor-negative breast cancer', Cancer Research, 71, pp. 941 - 941, http://dx.doi.org/10.1158/1538-7445.am2011-941

Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Shirley Liu X; Brown M, 2011, 'Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer', Cancer Cell, 20, pp. 119 - 131, http://dx.doi.org/10.1016/j.ccr.2011.05.026

Back to profile page